Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jupiter Neurosciences (JUNS) Gains from Investment Securities (2024 - 2025)

Jupiter Neurosciences (JUNS) has disclosed Gains from Investment Securities for 2 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 267.58% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 267.58% year-over-year, with the annual reading at $1.1 million for FY2025, 267.58% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $1.1 million at Jupiter Neurosciences, roughly flat from $1.1 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $10.6 million in Q1 2025, with the low at $250000.0 in Q2 2025.